Highfill, Steven L.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 767

CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T cell potency and toxicity: updated results from a phase I anti-CD22 CAR T cell trial

Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 421

Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas

Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 329

Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics

Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 107

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells

Stroncek, D. F., Lee, D. W., Ren, J., Sabatino, M., Highfill, S., Khuu, H., Shah, N. N., Kaplan, R. N., Fry, T. J., & Mackall, C. L. (2017) · Journal of Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 80

Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics

Elavia, N., Panch, S. R., McManus, A., Bikkani, T., Szymanski, J., Highfill, S. L., Jin, P., Brudno, J., Kochenderfer, J., & Stroncek, D. F. (2019) · Transfusion

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 43

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain

Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 16

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Mikkilineni, L., Manasanch, E. E., Natrakul, D., Brudno, J. N., Mann, J., Goff, S. L., Yang, J. C., Lam, N., Maric, I., Stetler-Stevenson, M., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 9